Identity
Native GLP-1 is an incretin hormone; it is distinct from long-acting receptor-agonist medicines.
Source-specific finding, not full clinical sign-off.
Peptide library
GLP-1 (Native)
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
Alternate assignment in the small infusion study is not concealed randomization. Continuous infusion of native GLP-1 differs from long-acting analogues; exposure, tolerability and product instructions cannot be shared.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
20 patients with type 2 diabetes, assigned alternately to infusion or saline.
What the sources found
Six weeks of continuous infusion improved selected glycemic measures; alternate allocation is not concealed randomization.
Regulatory scope
Current authorization must be checked for the exact product, indication and jurisdiction.
What remains unknown
Limited selected-source check, not an exhaustive review. Full methods, complete safety, exact formulation/route pharmacokinetics, stability and current jurisdictional authorization remain outstanding.
How it works
Native GLP-1 is an incretin hormone; it is distinct from long-acting receptor-agonist medicines.
Read the source-specific findings; biological activity is not equivalent to a clinical treatment benefit.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Reported adverse effects
- The pilot reported no important side effects, but was too small to establish comprehensive safety.
Source-specific finding, not full clinical sign-off.
Contraindications
- Full clinical contraindication and interaction assessment remains outstanding.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
Six weeks of continuous infusion improved selected glycemic measures; alternate allocation is not concealed randomization.
Source-specific finding, not full clinical sign-off.
Adverseeffects
The pilot reported no important side effects, but was too small to establish comprehensive safety.
Source-specific finding, not full clinical sign-off.
References
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. 2002.
PMID: 11897280
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.